Navigation Links
Dr. Paul Greengard, Karolinska Institutet's Bicentennial Gold Medal Recipient
Date:9/23/2010

NEW YORK, Sept. 23 /PRNewswire-USNewswire/ -- Dr. Paul Greengard, a Nobel Prize-winning neurobiologist and director of the Fisher Center for Alzheimer's Disease Research at The Rockefeller University, will receive the Karolinska Institutet's Bicentennial Gold Medal on September 23rd, 2010.  This medal is the highest award conferred by Karolinska Institutet during its 200th anniversary celebrations, and recognizes the work of an individual not permanently located at the Karolinska Institutet, who has contributed to the esteemed Swedish university's activities.  Since 1901, the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine.

"Dr. Greengard is one of the most prominent scientists of this century," says Harriet Wallberg-Henriksson, President of Karolinska Institutet.  "His seminal work has revealed several of the mechanisms behind psychiatric diseases.  He has been a mentor for generations of Karolinska Institutet scientists, who have been inspired by his scientific leadership and by his extraordinary capacity to reveal the biological meaning and medical implications of a series of unexpected observations from the laboratory."

Dr. Greengard has authored over 1,000 major scientific publications, and on September 2, 2010, he published an article in the scientific journal Nature that has been lauded as a potential paradigm shift in how Alzheimer's will be studied, and possibly treated, in the future. The article, entitled "Gamma-secretase Activating Protein is a Therapeutic Target for Alzheimer's Disease," outlines the discovery of a protein in the brain that stimulates the production of beta-amyloid, a protein in the brain believed to be one of the biological causes of Alzheimer's disease.

Dr. Greengard is a member of the National Academy of Sciences and has received more than 50 awards and honors.  In 2000, Dr. Paul Greengard, together with his wife, the renowned sculptor, Ursula von Rydingsvard, used his Nobel Prize honorarium to fund the Pearl Meister Greengard Prize, an award for women scientists named in honor of Greengard's mother, Pearl Meister Greengard, who died giving birth to him. The award is to combat discrimination against women in science, since, as Greengard observed, "Women are not yet receiving awards and honors at a level commensurate with their achievements."

The Karolinska Institutet's Gold Medal will be presented to Greengard on September 23rd at the residence of the Swedish ambassador to the United States in Washington, D.C.

Mr. Kent L. Karosen, President and CEO of the Fisher Center for Alzheimer's Research Foundation adds, "On behalf of the Fisher Center Foundation, I want to congratulate Dr. Greengard on this very prestigious award.  Dr. Greengard's contribution to Alzheimer's research has shaped the course of modern investigation into the causes and possible treatment of the disease, and his recent findings continue to open new avenues of study.  We are honored to have such a world prominent scientist directing the work of our research center."  

The Fisher Center for Alzheimer's Research Foundation is a leading source of funding for Alzheimer's research and education. We serve Alzheimer's patients and their families by seeking to understand the causes of, discover a cure for, and improve the lives of people with Alzheimer's disease.  Nobel laureate Dr. Paul Greengard directs the Foundation's team of internationally renowned scientists.  Of the money raised by the Foundation, only 8 cents out of every dollar is used for overhead and administrative purposes.  For more information about the Fisher Center for Alzheimer's Research Foundation, visit www.ALZinfo.org


'/>"/>
SOURCE Fisher Center for Alzheimer’s Research Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Torbjorn Bjerke Appointed as new CEO for Karolinska Development
2. Karolinska Development and Kurma Biofund to Enter Strategic Partnership
3. Karolinska Development and Uminova Invest Sign Co-operation Agreement
4. Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma
5. Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
6. Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial
7. Karolinska Development Closes Fully Subscribed New Share Issue
8. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
9. Genetics Entrepreneur Jonathan Rothberg Wins CT Medal of Technology
10. J. Craig Venter, Ph.D. to Receive National Medal of Science From President Obama
11. 7-Time Olympic Medalist Shannon Miller Endorses StemCyte
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Belgium (PRWEB) , ... February 16, 2017 , ... ... (SIOTAD) framework primarily aimed at the agricultural industry. Pilot studies are about to get ... products through IoT, Big Data and 5G innovations. The concept is expected to be ...
(Date:2/16/2017)... 16, 2017  MDNA Life Sciences Inc. (MDNA), ... liquid biopsy tests based on the mitochondrial genome, ... license agreement with its first international commercial partner, ... test for prostate cancer, the Prostate Mitomic Test ... This is the first overseas appointment for MDNA ...
(Date:2/16/2017)... --  Biostage, Inc. (Nasdaq: BSTG ), ... organ implants to treat cancers and other life-threatening conditions ... closing on February 15, 2017 of its previously announced ... warrants to purchase 20,000,000 shares of common stock, for ... priced at $0.40 per share of common stock, with ...
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. (NASDAQ: ... development and sale of advanced technology solutions and products ... today announced the addition of new cohorts of PDX ... new models will expand Champions, product line in hepatocellular ... neck cancer, AML, and non-small cell lung cancer (including ...
Breaking Biology Technology:
(Date:2/3/2017)... 3, 2017  Texas Biomedical Research Institute announced that its ... Schlesinger as the Institute,s new President and CEO. Dr. ... 31, 2017. He is currently the Chair of the Department ... for Microbial Interface Biology at Ohio State University. ... President and CEO of Texas Biomed," said Dr. James ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/2/2017)... 1, 2017  Central to its deep commitment ... worldwide, The Japan Prize Foundation today announced the ... pushed the envelope in their respective fields of ... scientists are being recognized with the 2017 Japan ... only contribute to the advancement of science and ...
Breaking Biology News(10 mins):